Combination therapy for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests combining two immunotherapy drugs with chemotherapy and sometimes another drug called bevacizumab, followed by radiation and chemotherapy. It aims to see if this approach can better treat advanced cervical cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cervical cancer called squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- Your cancer must be at a certain stage or have large tumors or lymph nodes.
- You must be a woman between 18 and 75 years old.
- You must be generally healthy enough to receive treatment (able to care for yourself and up and about).
- You must not have had any prior cancer treatment for cervical cancer, such as radiation, chemotherapy, or immunotherapy.
- You must be willing to provide tissue, blood, urine, stool, and vaginal secretion samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together for people with cervical cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease better than current options.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This study tests a new combination of drugs for women with advanced cervical cancer that has not been previously treated. The goal is to see if the combination can shrink tumors or slow down the cancer, and to check its safety.
Hear when a new Cervical Cancer Stage IVA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.